Evidence map›Paper›PMID 35822448›Full record

ArticleGenes, chromosomes & cancer2023

3'RNA and whole-genome sequencing of archival uterine leiomyomas reveal a tumor subtype with chromosomal rearrangements affecting either HMGA2, HMGA1, or PLAG1.

Vilja Jokinen, Miika Mehine, Siiri Reinikka, Sara Khamaiseh, Terhi Ahvenainen, Anna Äyräväinen, Päivi Härkki, Ralf Bützow, Annukka Pasanen, Pia Vahteristo

Open access · hybridAbstract read
In one paragraph

Article in Genes, chromosomes & cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. CD34-positive pleomorphic uterine sarcoma with NUDT3::RAD51B fusion.Virchows Archiv : an international journal of pathology · 2025
    Article
  9. Article
  10. Article
  11. Mechanism of Endometrial Receptivity Affected by Fibroids.American journal of reproductive immunology (New York, N.Y. : 1989) · 2024
    Review
  12. Uterine leiomyoma with RAD51B::NUDT3 fusion: a report of 2 cases.Virchows Archiv : an international journal of pathology · 2024
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Vilja JokinenApplied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland.
Miika MehineApplied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland.
Siiri ReinikkaApplied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland.
Sara KhamaisehApplied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland.
Terhi AhvenainenApplied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-9926-5452
Anna ÄyräväinenApplied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland.
Päivi HärkkiDepartment of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Ralf BützowApplied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland.
Annukka PasanenApplied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland.
Pia VahteristoApplied Tumor Genomics Research Program, University of Helsinki, Helsinki, Finland.
University of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Uterine leiomyomas, or fibroids, are very common smooth muscle tumors that arise from the myometrium. They can be divided into distinct molecular subtypes. We have previously shown that 3'RNA-sequencing is highly effective in classifying archival formalin-fixed paraffin-embedded (FFPE) leiomyomas according to the underlying mutation. In this study, we performed 3'RNA-sequencing with 111 FFPE leiomyomas previously classified as negative for driver alterations in mediator complex subunit 12 (MED12), high mobility group AT-hook 2 (HMGA2), and fumarate hydratase (FH) by Sanger sequencing and immunohistochemistry. This revealed 43 tumors that displayed expression features typically seen in HMGA2-positive tumors, including overexpression of PLAG1. We explored 12 such leiomyomas by whole-genome sequencing to identify their underlying genomic drivers and to evaluate the feasibility of detecting chromosomal driver alterations from FFPE material. Four tumors with significant HMGA2 overexpression at the protein-level served as controls. We identified chromosomal rearrangements targeting either HMGA2, HMGA1, or PLAG1 in all 16 tumors, demonstrating that it is possible to detect chromosomal driver alterations in archival leiomyoma specimens as old as 18 years. Furthermore, two tumors displayed biallelic loss of DEPDC5 and one tumor harbored a COL4A5-COL4A6 deletion. These observations suggest that instead of only HMGA2-positive leiomyomas, a distinct leiomyoma subtype is characterized by rearrangements targeting either HMGA2, HMGA1, or PLAG1. The results indicate that the frequency of HMGA2-positive leiomyomas may be higher than estimated in previous studies where immunohistochemistry has been used. This study also demonstrates the feasibility of detecting chromosomal driver alterations from archival FFPE material.

Indexed as

LeiomyomaUterine NeoplasmsChromosome AberrationsDNA-Binding ProteinsFemaleFumarate HydrataseHMGA1a ProteinHMGA2 ProteinHumansMutationRNATranscription FactorsDNA-Binding ProteinsFumarate HydrataseHMGA1a ProteinHMGA2 ProteinPLAG1 protein, humanRNATranscription Factors3′RNA-sequencingchromosomal rearrangementformalin-fixed paraffin-embedded tissueuterine fibroiduterine leiomyomawhole-genome sequencing

Identifiers

PMID35822448
PMCPMC9804854
OpenAlexW4285085911

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.